GlassScriptPhysician profile
Pauline Morrow
NPI 1629142484
$5,424.94
in general payments reported to CMS, 2019-2025
24 companies · $526 in 2025
The $526 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $961 · 2022: $676 · 2023: $2,254 · 2024: $1,008 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187 · Travel and Lodging: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.44 |
| Travel and Lodging | $600.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $968.19 | 2021-2025 | |
| Merz North America, INC. | $916.51 | 2022-2025 | Xeomin |
| Ucb, INC. | $568.27 | 2022-2024 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $382.07 | 2021-2024 | |
| Revance Therapeutics, INC. | $323.40 | 2024-2025 | Daxxify |
| Genzyme Corporation | $259.63 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $256.55 | 2022-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $237.64 | 2021-2025 | Cabtreo, Siliq, Arazlo |
| Incyte Corporation | $195.44 | 2022-2023 | Opzelura |
| Almirall LLC | $180.98 | 2021-2023 | Klisyri |
| Dermavant Sciences, INC. | $180.24 | 2023-2024 | Vtama |
| Epi Health, LLC | $172.22 | 2021 | |
| Arcutis Biotherapeutics, INC. | $166.30 | 2023-2024 | Zoryve |
| Lilly USA, LLC | $156.39 | 2023-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $116.24 | 2021-2025 | Dupixent |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $72.15 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.42 | 2022-2023 | Sotyktu |
| Journey Medical Corporation | $40.52 | 2022 | |
| Pfizer INC. | $36.26 | 2021 | |
| Leo Pharma INC. | $35.50 | 2022 | |
| Amgen INC. | $35.32 | 2021 | |
| Sun Pharmaceutical Industries INC. | $24.56 | 2023 | Winlevi |
| Botanix Sb INC | $17.01 | 2025 | Sofdra |
| Janssen Biotech, INC. | $13.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.